Vivos Therapeutics (VVOS) Assets Average (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Assets Average data on file, last reported at $25.1 million in Q1 2026.

• Quarterly Assets Average rose 88.94% year-over-year to $25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.1 million (up 88.94% YoY) and the FY2025 annual result came in at $20.2 million, up 55.44% from the prior year.
• Assets Average eased to $25.1 million in Q1 2026 per VVOS's latest filing, from $25.4 million in the prior quarter.
• Across five years, Assets Average topped out at $31.6 million in Q1 2022 and bottomed at $10.5 million in Q4 2023.
• The 5-year median for Assets Average is $15.6 million (2024), against an average of $18.5 million.
• The widest annual swing landed in 2022, when Assets Average tumbled 57.01%; it then surged 88.94% in 2026.
• Tracing VVOS's Assets Average over 5 years: stood at $16.1 million in 2022, then sank by 34.47% to $10.5 million in 2023, then jumped by 45.54% to $15.3 million in 2024, then jumped by 65.83% to $25.4 million in 2025, then decreased by 1.18% to $25.1 million in 2026.
• Per Business Quant, the three latest VVOS Assets Average figures stand at $25.1 million (Q1 2026), $25.4 million (Q4 2025), and $25.8 million (Q3 2025).

Peer Comparison